SG11201808237UA - Substituted indole compound derivatives as dengue viral replication inhibitors - Google Patents

Substituted indole compound derivatives as dengue viral replication inhibitors

Info

Publication number
SG11201808237UA
SG11201808237UA SG11201808237UA SG11201808237UA SG11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA
Authority
SG
Singapore
Prior art keywords
leuven
international
compounds
dengue viral
turnhoutseweg
Prior art date
Application number
SG11201808237UA
Inventor
Dorothée Alice Marie-Eve Bardiot
Jean-François Bonfanti
Erwin Coesemans
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SG11201808237UA publication Critical patent/SG11201808237UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111 HO 11111 0111011110011111H101011111110111011 1111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/167952 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (74) Agent: VERBERCKMOES, Mr. Filip; J&J Patent Law A61K 31/404 (2006.01) C07F 9/00 (2006.01) Department Turnhoutseweg 30, 2340 Beerse (BE). A61P 31/12 (2006.01) C07D 491/048 (2006.01) C07D 209/14 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/EP2017/057662 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 31 March 2017 (31.03.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (25) Filing Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (30) Priority Data: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 16163482.9 1 April 2016 (01.04.2016) EP ZA, ZM, ZW. (71) Applicants: JANSSEN PHARMACEUTICALS, INC. (84) Designated States (unless otherwise indicated, for every [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ kind of regional protection available): ARIPO (BW, GH, New Jersey 08560 (US). KATHOLIEKE UNI- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, VERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 3000 Leuven (BE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: BARDIOT, Dorothee Alice Marie-Eve; c/o LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, _ (Heverlee) (BE). BONFANTI, Jean-Francois; c/o GW, KM, ML, MR, NE, SN, TD, TG). Janssen-Cilag 1 rue Camille Desmoulins, TSA 91003, = 92787 Issy-les-Moulineaux Cedex 9 (FR). COESEMANS, Declarations under Rule 4.17: Erwin; Janssen Pharmaceutica NV Turnhoutseweg 30, — be c/o as to applicant's entitlement to apply for and granted a 2340 Beerse (BE). KESTELEYN, Bart Rudolf Romanie; patent (Rule 4.1700) = c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 — Beerse (BE). MARCHAND, Arnaud Didier M; c/o Cis- Published: Leuven Gaston Geenslaan 2, 3001 Leuven — international 21(3)) tim vzw (Hever- with search report (Art. lee) (BE). RABOISSON, Pierre Jean-Marie Bernard; with sequence listing part of description (Rule 5.2(a)) = c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 = Beerse (BE). = = = = = = = = 1-1 ei kr) 0\ IN 1-1 (54) Title: SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS 1-1 © (57) : The present invention concerns substituted indole compounds, methods to prevent or treat dengue viral infections by N using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or 0 prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination prepara- tions of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
SG11201808237UA 2016-04-01 2017-03-31 Substituted indole compound derivatives as dengue viral replication inhibitors SG11201808237UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163482 2016-04-01
PCT/EP2017/057662 WO2017167952A1 (en) 2016-04-01 2017-03-31 Substituted indole compound derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
SG11201808237UA true SG11201808237UA (en) 2018-10-30

Family

ID=55650310

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808237UA SG11201808237UA (en) 2016-04-01 2017-03-31 Substituted indole compound derivatives as dengue viral replication inhibitors

Country Status (21)

Country Link
US (1) US10730884B2 (en)
EP (1) EP3436004B1 (en)
JP (2) JP7007290B2 (en)
KR (1) KR102359766B1 (en)
CN (1) CN109069482B (en)
AU (1) AU2017240076A1 (en)
BR (1) BR112018068956A2 (en)
CA (1) CA3013408A1 (en)
CL (1) CL2018002784A1 (en)
CO (1) CO2018009996A2 (en)
CR (1) CR20180494A (en)
EA (1) EA201892200A1 (en)
EC (1) ECSP18073264A (en)
ES (1) ES3010298T3 (en)
IL (1) IL261947A (en)
MA (1) MA44502A (en)
MX (1) MX2018011786A (en)
PH (1) PH12018502026A1 (en)
SG (1) SG11201808237UA (en)
SV (1) SV2018005750A (en)
WO (1) WO2017167952A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
HRP20210847T1 (en) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. SUBSTITUTED INDOL DERIVATIVES AS DENGER VIRUS REPLICATION INHIBITORS
MX2018011788A (en) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors.
KR102359766B1 (en) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 Substituted Indole Compound Derivatives as Dengue Virus Replication Inhibitors
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Indolein derivatives substituted as viral reproductive inhibitors of Fennec fever
EA201992782A1 (en) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. SUBSTITUTED INDOLINE DERIVATIVES AS MONEY VIRUS REPLICATION INHIBITORS
CN110753682B (en) 2017-05-22 2023-06-30 杨森制药公司 Substituted indoline derivatives as dengue virus replication inhibitors
CN108947948B (en) * 2018-06-12 2021-07-20 湖南大学 A kind of N-aryl naphthofuranone imine compound and its synthetic method
CN108586404A (en) * 2018-06-12 2018-09-28 湖南大学 A kind of synthetic method of N- aryl naphtho- furanone imine compound
WO2026057013A1 (en) * 2024-09-14 2026-03-19 华武生物医药技术(湖北)有限责任公司 Dengue virus replication inhibitor, preparation method therefor and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2006035061A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
JP2008530124A (en) 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド Compositions and methods for treating or preventing flavivirus infections
EP2203168B1 (en) * 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
JP5559174B2 (en) 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Cold sensation-menthol receptor antagonist
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CA2785563C (en) 2010-01-15 2019-05-14 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
KR102290189B1 (en) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN116987080A (en) 2014-01-31 2023-11-03 百时美施贵宝公司 Macrocyclic compounds with heterocyclic P2′ groups as factor XIA inhibitors
ME03344B (en) * 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc MONO OR DI SUBSTITUTED INDOLES AS DENGUE VIRUS REPLICATION INHIBITORS
NO2721243T3 (en) 2014-10-01 2018-10-20
AU2015326930B2 (en) 2014-10-01 2020-03-26 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (en) 2015-02-23 2017-05-24 Lilly Co Eli BACE1 SELECTIVE INHIBITORS
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
MX374683B (en) 2015-11-03 2025-03-04 Zoetis Services Llc SOL-GEL POLYMERIC COMPOUNDS AND THEIR USES.
HRP20210847T1 (en) * 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. SUBSTITUTED INDOL DERIVATIVES AS DENGER VIRUS REPLICATION INHIBITORS
ES2804580T3 (en) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Heterocyclic compound
MX2018011788A (en) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors.
AU2017241837B2 (en) 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MY210545A (en) 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
EP3436457B1 (en) 2016-04-01 2022-07-20 Basf Se Bicyclic compounds
KR102359766B1 (en) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 Substituted Indole Compound Derivatives as Dengue Virus Replication Inhibitors
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
PT3436079T (en) 2016-04-01 2021-10-06 Kite Pharma Inc CHIMERIC AND T-CELL ANTIGEN RECEIVERS AND METHODS OF USE
KR20200068750A (en) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 Chimeric receptors and methods of use thereof
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Indolein derivatives substituted as viral reproductive inhibitors of Fennec fever
CN110753682B (en) 2017-05-22 2023-06-30 杨森制药公司 Substituted indoline derivatives as dengue virus replication inhibitors
EA201992782A1 (en) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. SUBSTITUTED INDOLINE DERIVATIVES AS MONEY VIRUS REPLICATION INHIBITORS

Also Published As

Publication number Publication date
JP2022009166A (en) 2022-01-14
SV2018005750A (en) 2018-11-15
ES3010298T3 (en) 2025-04-02
CN109069482A (en) 2018-12-21
MX2018011786A (en) 2019-05-20
BR112018068956A2 (en) 2019-01-22
KR102359766B1 (en) 2022-02-07
US10730884B2 (en) 2020-08-04
JP7007290B2 (en) 2022-01-24
PH12018502026A1 (en) 2019-02-11
EP3436004B1 (en) 2024-12-11
EP3436004A1 (en) 2019-02-06
MA44502A (en) 2019-02-06
CA3013408A1 (en) 2017-10-05
CN109069482B (en) 2022-04-05
EP3436004C0 (en) 2024-12-11
ECSP18073264A (en) 2018-10-31
WO2017167952A1 (en) 2017-10-05
JP2019511502A (en) 2019-04-25
AU2017240076A1 (en) 2018-08-09
CO2018009996A2 (en) 2018-09-28
CL2018002784A1 (en) 2018-12-14
US20190276467A1 (en) 2019-09-12
CR20180494A (en) 2019-01-29
EA201892200A1 (en) 2019-03-29
IL261947A (en) 2018-10-31
KR20180130502A (en) 2018-12-07

Similar Documents

Publication Publication Date Title
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201809708PA (en) Physiologically balanced injectable formulations of fosnetupitant